An observational study in AL Amyloidosis, Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 4 sites in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia — 6 open to participants now, 6 under way, none of them phase 3. Immunoglobulin Light-chain Amyloidosis · Fondazione IRCCS Policlinico San Matteo di Pavia.
Among the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia, this one is the only one that started in 2023, is one of 7 observational ones, and was the 10th registered.
239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.
Browse Immunoglobulin Light-chain Amyloidosis studies →6 of the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia are open now, in 6 countries. Recruiting first, the newest first:
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–99
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–99
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Germany, Italy, Netherlands and 3 more countries
Ages 18–99
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–99
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18–99
By country, each count listing its studies:
Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 1
First in 2012; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 760 is above the median of 275 across 42 observational studies indexed under Immunoglobulin Light-chain Amyloidosis.
Median enrollment 28 across the 6 interventional studies, 400 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 258 studies on the registry; 115 are open to participants now.
3 of the studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05444920Fondazione IRCCS Policlinico San Matteo di PaviaThe Italian Transthyretin Amyloidosis Web-Network | 2026-12-31 |
| NCT04839003Fondazione IRCCS Policlinico San Matteo di PaviaA Registry of AL Amyloidosis (ReAL) | 2027-05 |
| NCT07448779Fondazione IRCCS Policlinico San Matteo di PaviaInvestigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment | 2027-05-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to:
AL amyloidosis (AL) is a rare, severe protein conformational disease caused by misfolding and extracellular deposition of patients-specific monoclonal immunoglobulin light chains in form of amyloid fibrils. This process can affect virtually any body site and result in potentially fatal organ dysfunction.
In a significant proportion of cases, AL is diagnosed late, when advanced, often irreversible organ involvement limits therapeutic options and greatly limits survival. Thus, efforts at promoting early diagnosis are urgently needed.
The presence of a monoclonal protein (M protein) or an abnormally increased concentration of serum free LCs (FLCs) invariably precedes clinically overt AL amyloidosis by several years. Moreover, about 95% of patients with AL have an altered FLC ratio (FLCR) at diagnosis. Yet, AL is often diagnosed late also in patients with known monoclonal gammopathy under hematological follow-up. Screening of at-risk patients with biomarkers of early amyloid organ involvement has been advocated, but not largely implemented.
Diagnosis and management of AL patients require access to sophisticated technologies and expertise available at large tertiary Amyloid Centers. Yet, new models of patients' care are required to intercept those patients who cannot travel to distant, tertiary centers, in order to provide state-of-the-art care to all and to be able to analyze and describe the natural history of the disease in a contemporary, real-world setting.
New molecular features associated with the propensity of light chains to form amyloid are emerging, but their potential clinical utility is unknown. Building on >30 years-experience of the Italian Referral Center for Systemic Amyloidoses and leveraging on an already existing disease registry and a one-of-a-kind biorepository of clinically annotated biological samples, the study plans to extend and corroborate the activity of the Italian Amyloidosis Network, through the involvement of large Hematology Departments strategically distributed across the Country and the establishment of a structured program of patients' referral and sample/data transfer.
The study will be conducted as follows:
Part A: an active biomarker-based surveillance of pre-symptomatic signs of amyloid organ involvement in at-risk subjects (patients with MGUS and aFLCR and patients with SMM) will be implemented in the participating Italian Hematologic Departments. This will enable the verification of the feasibility of such biomarker-based screening, allow the description of baseline characteristics of at-risk patients, and promote early diagnosis of AL amyloidosis.
Part B: newly diagnosed AL amyloidosis patients (either from Part A or from patients with clinically overt AL amyloidosis evaluated in the frame of routine clinical assessments) will be either referred to the Amyloidosis Research and Treatment Center in Pavia or managed locally, with clinical data prospectively entering a disease registry and diagnostic leftovers from biospecimens stored in a biorepository. This will aim to increase referral and increment inclusion of real-world cases of AL amyloidosis in the disease registry and linked biorepositories, as well as patients' enrollment in other already approved and funded pre-clinical and clinical studies on basic disease mechanisms, as well as new diagnostic/therapeutic approaches in AL amyloidosis.
Part C: exploiting data collected from patients enrolled in both part A and part B, the clinical utility of clonal light chain profiling (including light chain sequencing, evaluation of the N-glycosylation status, and artificial intelligence-based amyloidogenicity prediction) will be assessed.
The participating Departments of Hematology will be involved in screening at-risk patients with monoclonal gammopathies and refer suspected/confirmed AL cases to the Amyloidosis Center in Pavia.
PART A
Inclusion Criteria:
Exclusion Criteria:
PART B
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Patients with MGUS and aFLCR and patients with SMM undergoing an active, biomarker-based screening of presymptomatic amyloid organ involvement. Part B: Newly diagnosed patients with AL amyloidosis identified through Part A or with clinically overt AL amyloidosis evaluated in the frame of routine clinical assessments and referred to the Amyloidosis Research and Treatment Center in Pavia or managed locally at the participating Italian Hematologic Departments
Other: no intervention
no intervention
Assess proportion of patients with newly diagnosed AL identified through the biomarker-based screening of at-risk patient
Part A of the study: the proportion of patients with newly diagnosed AL through the biomarker-based screening of at-risk patients with a known monoclonal gammopathy will be identified.
Time frame: 2 years
Assess the proportion of patients with deep haematological response after frontline therapy (best response evaluation) in the new enhanced, contemporary, real-world series of AL patients enrolled during the study.
Part B of the study: The proportion of patients with deep hematological response after frontline therapy will be assessed
Time frame: 2 years
3. Identify associations of clonal light chain features with different clinical features at baseline.
Part C of the study: Associations of clonal light chain features with different clinical features at baseline, including organ tropism and clonal burden, will be assessed.
Time frame: 2 years
Description of the baseline characteristics and 6-months outcome, as well as the time to AL development for patients with AL identified through the biomarker-based screening
Part A: the baseline characteristics and 6-months outcome, as well as the time to AL development for patients with AL identified through the biomarker-based screening will be evaluated
Time frame: 6 months
Description of the baseline characteristics of MGUS/SMM patients with abnormal FLCR
Part A: the baseline characteristics of MGUS/SMM patients with abnormal FLCR will be described
Time frame: 2 years
Identification of clinical and biological correlates of hematological response
part B: clinical and biological correlates of hematological response will be identified
Time frame: 2 years
To verify whether implementing a dedicated pipeline for referral of AL patients to the National Referral Center will increase the proportion of patients from spoke centers
Part B: it will be verified if implementing a dedicated pipeline for referral of AL patients to the National Referral Center will increase the proportion of patients from spoke centers
Time frame: 2 years
Identification of associations of clonal light chain features with event-free survival
Part C: associations of clonal light chain features with event-free survival will be identified.
Time frame: 2 years
Validation of existing algorithms for predicting AL amyloidosis status
Part C: The diagnostic performance of existing algorithms for predicting clonal light chain amyloidogenicity will be evaluated.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for May 2026, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immunoglobulin Light-chain Amyloidosis →
Fondazione IRCCS Policlinico San Matteo di Pavia →